newstock.ai
← Back

DHRDanaher

$218.49+1.34%Delayed market dataLife sciencesMedtech & life sciences · 10 peers →

What's moving this stock lately

No recent news affecting this stock

🎯 Market expectations

Estimate coverage High · 79/100

Nasdaq analyst consensus · the pre-news baseline

Next quarter (Sep 2026) consensus$1.96Estimate range $1.91 ~ $2.10 · 9 analysts
History: actual vs consensusavg +5.7%
  • Jun 2026$1.94 vs $1.84+5.43%
  • Mar 2026$2.06 vs $1.94+6.19%
  • Dec 2025$2.23 vs $2.22+0.45%
  • Sep 2025$1.89 vs $1.71+10.53%

The takeaway

Recent results have exceeded consensus by an average of +5.7%, which may have raised expectations for the next report.

Analyst estimates, not our forecast · not investment advice

🏛️ Company factsSEC filings + FINRA official data

Annual revenue $24.6B · latest quarter up 5.5% YoY · profitable (FY net income $3.6B) · short activity within its normal range.

FY revenue

$24.6B

2025-12

Latest Q YoY

+5.5%

Gross margin

59.1%

FY net income

$3.6B

Diluted EPS

$5.07

Short volume

47.8%

20d avg 42.1% · normal

🐋 5%+ ownership filings (last 180d)

The following investors reported beneficial ownership of more than 5% in recent SEC filings. "Activist" filers stated an intent to influence control of the company; "Passive" indicates the filer did not report such an intent.

🕰️ Price × news · analysis history

Drag to pan, scroll to zoom · real daily bars and volume

▂ volume
Unlock the full analysisStart my free trial

Current conviction

Crowding

Risk temperature

Tail risk

Triggers

Money flow

Insider signals

Unlock the full analysis

See every affected stock, second-order impact and risk factor. Try Pro free for 7 days — no credit card required.

Start my free trial